HB-201 is under clinical development by Hookipa Pharma and currently in Phase II for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HB-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HB-201 (TheraT) is under development for the prevention of human papillomavirus 16 (HPV 16) driven oropharynx cancer, metastatic squamous cell carcinoma, cervical cancer, head and neck cancer squamous cell carcinoma and melanoma. The vaccine candidate is administered by intratumor and intravenous routes. It is developed based on TheraT platform which generates replication attenuated viral vectors expressing gene of interest. The vaccine candidate acts by targeting human papillomavirus protein E6 and E7.
It was also under development for anal cancer, penile cancer, vaginal, vulvar cancer and cervical cancer.
Hookipa Pharma overview
Hookipa Pharma (Hookipa) is a clinical-stage biopharmaceutical company that develops novel class of immunotherapeutics against infectious diseases and cancers. Its pipeline products include HB-101, a prophylactic cytomegalovirus vaccine candidate; HB-202 and HB-201, immuno-oncology product candidates for the treatment of human papillomavirus-positive cancers; and HB-301, targeting prostate cancer. Hookipa’s proprietary arenavirus-based technologies, VaxWave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce antigen specific cytotoxic T cells and pathogen-neutralizing antibodies for prophylactic and therapeutic purposes activating body’s immune response. The company collaborates with Gilead Sciences Inc for the development of immunotherapies to treat HIV and Hepatitis B. It operates a research and preclinical development center in Vienna, Austria. Hookipa is headquartered in New York City, New York, the US.
For a complete picture of HB-201’s drug-specific PTSR and LoA scores, buy the report here.